Fundz
Following Partner Therapeutics?

Get the free weekly product launch digest

The latest product launches, like Partner Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New product launches, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Launch Trends

See who's moving and how much in your market

No credit card required Weekly product launch digest

Partner Therapeutics, Inc. announces publication of eNRGy trial results for zenocutuzumab-zbco (BIZENGRI®) in treating NRG1+ cancer.

Feb 05, 2025•over 1 year ago
MassachusettsBiotechnologyHealth CareMedicalTherapeutics

Product Description

Partner Therapeutics, Inc. has announced the publication of the results from the Phase 2 eNRGy clinical trial evaluating zenocutuzumab-zbco (BIZENGRI®) for patients with NRG1 gene fusions. The trial highlighted notable response rates and safety data, particularly for patients with advanced pancreatic cancer and NSCLC.

Company Information

Company

Partner Therapeutics

Location

Massachusetts, United States

About

Partner Therapeutics, Inc. (PTx) is a private, fully-integrated biotechnology company dedicated to advancing breakthrough therapies for patients with cancer. The company focuses on the development and commercialization of innovative drugs to address significant unmet medical needs. PTx has an exclusive agreement with Merus to develop, manufacture, and commercialize zenocutuzumab-zbco for the treatment of NRG1+ cancer. With a commitment to improving patient outcomes, PTx actively collaborates with leading medical institutions and researchers.

Predictive Intelligence
Strategic

ML-powered predictions for Partner Therapeutics's next move

Learn about Strategic plan

Product Launch Insights

Based on market data
Market expansion signals
New product launches often coincide with market expansion initiatives

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.